Neovascular age-related macular degeneration (AMD) has undergone substantial break-
throughs in diagnostic as well as therapeutic respect, with optical coherence tomography …

Age-related macular degeneration (AMD) is the leading cause of severe visual loss in
people aged 50 years or older in the developed world. In recent years, major advances have …

Age‐related macular degeneration (AMD) is the leading cause of legal blindness in elderly
people. Neovascular AMD (nAMD) is responsible for the majority of cases of severe visual …

Currently available evidence on predictors of anti-vascular endothelial growth factor (VEGF)
treatment response in neovascular age-related macular degeneration was reviewed. No …

Purpose To establish the predictive value of defined retinal morphologic parameters on
visual outcomes and re-treatment needs in patients with neovascular age-related macular …

Purpose: To determine if there is an association of vitreous attachment and wet age-related
macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. Methods …

Age-related macular degeneration (AMD) is the main cause of visual impairment and
blindness in people aged over 65 years in developed countries. Vascular endothelial growth …

Purpose To investigate the influence of the vitreomacular interface (VMI) on the functional
and anatomic efficacy of ranibizumab therapy in patients with neovascular age-related …

Age-related macular degeneration (AMD) is the leading cause of blindness in the Western
world. AMD is a multifactorial disorder but complement-mediated inflammation at the level of …

Purpose Intravitreal anti-vascular endothelial growth factor (VEGF) agents are effective in
the treatment of central involving diabetic macular oedema (DMO). Vitreoretinal interface …